Librela injection for dogs: side effects, how long it takes, pros and cons

Your vet has mentioned Librela. Or perhaps your dog is already on it and someone told you to Google the side effects. Or you have been watching your arthritic dog struggle for months and you want to know if this monthly injection is actually worth it.

Wherever you are in that conversation, I want to give you a genuinely honest guide — not a promotional summary, and not a scare piece either. Librela is one of the most significant developments in canine arthritis treatment in recent years, and it has genuinely helped a lot of dogs. It also has a safety profile that deserves to be discussed clearly and openly with every owner before they start.

In this guide I will explain exactly what Librela is and how it works, what the clinical trials showed, what the real-world side effects are including the ones the FDA has flagged, which dogs are most likely to benefit and which dogs should probably avoid it, and the practical questions every owner should ask their vet before starting.

What Is Librela and How Does It Work?

Librela is the brand name for bedinvetmab — a monoclonal antibody injection used for controlling pain associated with osteoarthritis in dogs. The FDA-approved injection is given to dogs once a month by a veterinarian, typically in a vet office setting.

The way it works is genuinely different from every pain medication that came before it. Traditional NSAIDs like meloxicam and carprofen reduce pain by suppressing inflammation in the joint. Librela works further upstream in the pain pathway — it targets a protein called Nerve Growth Factor, or NGF.

Bedinvetmab is a monoclonal antibody therapy that reduces pain signaling between the arthritic joint and the central nervous system by binding and neutralizing nerve growth factor (NGF). In simple terms: NGF is one of the key signals that tells the brain there is pain in the joint. Librela intercepts and neutralises that signal before it reaches the brain. The dog does not feel the pain because the message does not fully arrive.

This is why Librela can work in dogs who have not responded adequately to NSAIDs — it is not doing the same thing as those drugs, it is doing something different at a different point in the pain pathway. For many arthritic dogs, using both together gives better pain control than either alone.

Does Librela Actually Work? What the Evidence Shows

The clinical evidence for Librela's effectiveness is genuinely strong. A randomised, double-blind, non-inferiority study compared Librela to Galliprant (grapiprant) in 32 dogs with hip and/or stifle osteoarthritis. After 2 months, both groups showed significant improvement, and the authors concluded that Librela was at least as effective as Galliprant.

In the pivotal trials that led to FDA approval, dogs receiving Librela showed statistically significant reductions in pain scores compared to placebo, with owner assessments of their dog's mobility and comfort showing meaningful improvement. Many owners describe dogs who were previously reluctant to walk or play showing renewed interest and willingness to move within weeks of starting treatment.

You may notice improvements in your dog's mobility within a few days to weeks of the injection; however, it may take more than one month of use before optimal results are reached. If there is no improvement after the second injection, or if the dog does not continue to respond after subsequent injections, talk to your veterinary team about other pain management options.

In practice, I tell owners to give it two injections before making a judgement. Some dogs respond visibly within a week. Others take six to eight weeks before the full benefit is apparent. A dog who shows no meaningful improvement after two doses is unlikely to be a strong responder to this treatment.

What Are the Side Effects of Librela in Dogs?

This is the section I want to spend the most time on, because it is the most searched question — and because the honest answer is more nuanced than either "it is perfectly safe" or "it is dangerous."

Side effects seen in clinical trials

Side effects seen during clinical trials of bedinvetmab include mild reactions at the injection site — heat, swelling, and pain at the site of injection. These were generally minor and short-lived. In the preapproval studies, Librela was considered well-tolerated, and the FDA approved it as safe and effective based on that data.

Side effects reported after real-world use began

After Librela was approved by the FDA in May 2023 and introduced to the market, a wider range of adverse events began to be reported through the pharmacovigilance system. As of April 18, 2024, the FDA Center for Veterinary Medicine's database included 3,674 reports associated with Librela.

The adverse events identified and analysed by the FDA include ataxia, seizures, other neurological signs including paresis and recumbency, urinary incontinence, polyuria, and polydipsia. In some cases, death including euthanasia was reported as an outcome of these adverse events.

Two-thirds of the adverse event reports indicated clinical signs occurring within the first week after administration. Thirty percent of these signs occurred within the first day. Signs were observed after the initial dose of Librela in 70% of the reported cases. Approximately 30% of the cases reported showed no concurrent use of other products.

Additionally, there are reports of injection site reactions including swelling and warmth, lack of efficacy, death, allergic reactions, and immune-mediated disease including haemolytic anaemia and thrombocytopenia.

An important context note on these reports

I want to be transparent about something that matters when interpreting these numbers. The 3,674 adverse event reports sound alarming — but the FDA pharmacovigilance system is a passive reporting system, meaning it captures cases reported by owners and vets, not a controlled trial. It does not tell us what proportion of all treated dogs experienced problems, and it does not prove causation — a dog who had a seizure after receiving Librela may have had that seizure anyway, particularly given that senior arthritic dogs are more likely to have other health conditions.

The FDA has stated clearly that Librela was approved as safe and effective based on preapproval data, and that the adverse event reports do not change that approval status. The agency continues to monitor and publish new data on a rolling basis.

What the reports do tell us is that some dogs — particularly those with pre-existing neurological conditions, urinary problems, or immune conditions — appear to be at higher risk of adverse events. This is exactly the information that helps your vet make a better prescribing decision for your specific dog.

The rapidly progressive osteoarthritis concern

There is one more concern in the published literature that deserves honest mention. NGF modulates bone and cartilage turnover, and its inhibition is linked to accelerated joint degeneration in humans. In 2012, clinical trials of anti-NGF monoclonal antibodies in humans revealed rapidly progressive osteoarthritis, leading the FDA to impose a two-year clinical trial hold.

Only 89 dogs received more than three doses in Librela's pre-marketing clinical trials, and crucially, no radiographic screening for accelerated joint degeneration was conducted. Longer-term data in dogs is still accumulating. Long-term side effects occurring more than nine months after using bedinvetmab have not been evaluated.

This does not mean the risk of accelerated joint damage in dogs is confirmed — it means the long-term data in dogs is not yet complete, and some veterinary specialists are monitoring for this possibility. It is a conversation worth having with your vet, particularly if you are considering long-term use.

Which Dogs Are Most Likely to Benefit from Librela?

Librela tends to work best in the following situations:

• Dogs with confirmed osteoarthritis who have had a partial but incomplete response to NSAIDs — Librela can be used alongside NSAIDs to improve pain control without increasing NSAID doses

• Dogs who cannot tolerate NSAIDs due to kidney, liver, or gastrointestinal issues — since Librela works through an entirely different mechanism, it is not an NSAID and does not carry the same organ risks

• Dogs with significant arthritis pain affecting daily life and quality of life, where the benefit of better pain control clearly outweighs the risks

• Dogs whose owners can commit to monthly vet visits for administration and monitoring

Which Dogs Should Be Cautious or Avoid Librela?

Dogs with pre-existing medical issues including balance problems, trouble standing, seizures, and urinary conditions should be discussed carefully with your vet before starting Librela, given that these are among the post-marketing adverse events reported.

Additionally:

• Librela has not been evaluated in dogs with a history of cruciate ligament rupture in the past six months or in dogs less than 12 months old

• Dogs with known or suspected immune-mediated conditions should be assessed carefully, given the reports of haemolytic anaemia and thrombocytopenia

• Dogs with advanced kidney or liver disease — not because Librela directly harms these organs, but because these dogs may be more vulnerable if adverse events do occur

• Pregnant or breeding dogs — safety has not been established in these animals

How Is Librela Given and What Does the Process Look Like?

Librela is given as a subcutaneous injection — under the skin, usually at the scruff of the neck or the area between the shoulder blades. They will typically schedule an appointment for your dog every four weeks to administer the injection and observe your dog's response.

The injection is administered at the clinic, not at home. This is intentional — it ensures your vet can observe your dog's immediate response, adjust the dose if needed, and catch any early adverse reactions. The injection itself takes seconds and most dogs tolerate it with minimal reaction.

The dose is calculated based on your dog's body weight. Librela is available in different concentrations (5mg, 15mg, 20mg, and 30mg vials) to allow accurate weight-based dosing.

Can Librela Be Used Alongside Other Medications?

Yes, in most cases. One of the real advantages of Librela is that it works through a mechanism entirely different from NSAIDs, which means it can often be used alongside meloxicam, carprofen, or other anti-inflammatory medications to provide better combined pain control.

Regarding Librela and Metacam (meloxicam) together specifically — this combination is used clinically and is not contraindicated, but as with any combination of medications in an older dog, it should be done under vet supervision with appropriate monitoring of kidney function. The benefit of better pain control in a dog with significant arthritis often outweighs the modest additional monitoring burden.

Gabapentin, joint supplements, and physiotherapy can also be used alongside Librela without concern.

How Long Can a Dog Stay on Librela?

There is no defined upper limit on duration of treatment — it is intended as a long-term, ongoing monthly treatment for chronic arthritis pain. However, long-term side effects occurring more than nine months after using bedinvetmab have not been evaluated in formal clinical trials.

In practice, most vets reassess the benefit-risk balance with owners every six to twelve months. If the dog is responding well, quality of life is clearly improved, and no concerning signs have developed, continuing treatment is generally reasonable. If a dog is not responding or develops concerning signs, stopping Librela and discussing alternatives is always an option.

It is important to note that dogs may develop anti-bedinvetmab antibodies, which can result in Librela injections losing effectiveness over time. If your dog responded well initially but the effect seems to be wearing off, mention this to your vet — this antibody development is a recognised phenomenon and may prompt a reassessment of the treatment plan.

Pros and Cons of Librela — An Honest Summary

The genuine advantages

• Works through a different mechanism from NSAIDs — can be used in dogs who cannot tolerate anti-inflammatories

• Can be combined with NSAIDs for better pain control without increasing NSAID dose

• Monthly dosing is convenient — no daily tablet battles

• Strong clinical evidence for effectiveness in reducing arthritis pain

• Many dogs who were significantly limited by arthritis pain have shown meaningful improvement

• Not associated with the kidney or gastrointestinal side effects of long-term NSAID use

The genuine limitations and concerns

• Real-world adverse event reports include serious neurological signs, urinary changes, and immune reactions — these are rare but documented

• Long-term safety data beyond nine months is not yet available from formal trials

• Requires a monthly vet visit — it cannot be administered at home

• More expensive than daily NSAID tablets for most owners

• Some dogs develop antibodies that reduce effectiveness over time

• The rapidly progressive joint degeneration seen with similar drugs in humans has not been definitively ruled out in dogs

Questions to Ask Your Vet Before Starting Librela

• Does my dog have any pre-existing conditions that make Librela higher risk — particularly neurological, urinary, or immune conditions?

• Will my dog stay on their current NSAID alongside Librela, or will you be switching?

• What should I watch for in the first week after each injection?

• How will we know if it is working, and over what timeframe?

• What is the plan if we need to stop — is there an alternative we can move to?

• What monitoring will be done — blood tests, reassessments?

A Final Word from Dr. Waleed

I have seen Librela change dogs' lives. Dogs who were reluctant to walk, who flinched away from being touched, who spent most of the day lying still because movement hurt — returning to something much closer to their old selves after a few weeks of monthly injections. That is real, and it matters.

I have also read the FDA's adverse event data carefully. The reports of neurological signs, urinary changes, and immune reactions are real too — and they are why this is not a medication to start without a proper conversation about your specific dog's health history and risk profile.

My honest position: for the right dog — one with confirmed osteoarthritis, inadequate pain control on other medications, and without significant pre-existing neurological or immune conditions — Librela is a genuinely valuable tool that I recommend. The conversation with your vet should be about your dog specifically, not about the drug in the abstract.

Ask the questions. Get the monitoring plan. And if your dog responds well — as many do — you will likely feel it was worth it.

Frequently Asked Questions

What are the side effects of Librela injection in dogs?

In the clinical trials, the main side effect was mild injection site reactions — localised heat, swelling, or discomfort. Since real-world use began, the FDA has received reports of more significant adverse events including neurological signs such as ataxia and seizures, urinary changes including incontinence and increased thirst and urination, and rare reports of immune-mediated conditions such as haemolytic anaemia. Most adverse events were reported within the first week after administration. These serious effects appear to be uncommon, but they are documented and worth discussing with your vet, particularly if your dog has any pre-existing neurological or urinary conditions.

How long does it take for Librela to work in dogs?

Some dogs show improvement in mobility and comfort within a few days to two weeks of the first injection. Others take longer — it can take more than one month of treatment before the full benefit is apparent. Most vets recommend giving Librela at least two monthly injections before deciding whether it is working for your dog. If there is no meaningful improvement after the second injection, other pain management options should be discussed.

How long can a dog stay on Librela?

Librela is designed as an ongoing monthly treatment for chronic arthritis pain, with no defined upper limit on duration. However, formal clinical trial data on long-term safety beyond nine months does not yet exist. In practice, most vets reassess the benefit-risk balance every six to twelve months. Dogs who are responding well and showing no concerning signs can generally continue. Some dogs also develop antibodies against Librela over time that reduce its effectiveness — if this happens, your vet will discuss alternatives.

Can Librela be given with Metacam or other NSAIDs?

Yes, Librela and Metacam (meloxicam) or other NSAIDs can be used together, and this combination is used clinically to improve pain control in dogs who respond partially to either drug alone. Since Librela works through a different mechanism from NSAIDs, there is no direct pharmacological conflict. Your vet will monitor kidney function and overall health as they would with any combination treatment in a senior dog. This is a common and reasonable approach for dogs with significant arthritis pain.

What are the pros and cons of Librela for dogs?

The main advantages are that it works through a unique mechanism not shared by any other pain medication, it can be used in dogs who cannot tolerate NSAIDs, it can be combined with NSAIDs for better pain control, and many dogs show meaningful improvement in mobility and quality of life. The main limitations are the cost of monthly vet visits, the real-world adverse event reports including neurological and urinary signs, the absence of long-term clinical trial data beyond nine months, and the possibility of antibody development reducing effectiveness over time. For the right dog with adequate vet monitoring, the benefits often outweigh these concerns.

Is Librela safe for dogs?

The FDA reviewed the available clinical data and approved Librela as safe and effective for control of arthritis pain in dogs. In clinical trials it was well tolerated. Since real-world use began, the FDA has received and reviewed adverse event reports including some serious neurological and urinary effects — and has issued a Dear Veterinarian Letter informing vets of these findings while maintaining the approval. The current position is that Librela is appropriate for use in dogs with arthritis pain, with the understanding that dogs with pre-existing neurological, urinary, or immune conditions carry higher risk and should be assessed carefully before starting treatment.

Where is Librela injected in dogs?

Librela is given as a subcutaneous injection — under the skin, typically at the scruff of the neck or between the shoulder blades. It is administered at the vet clinic, not at home. The dose is calculated based on your dog's body weight, and Librela is available in different concentrations to allow accurate dosing. The injection itself takes only a few seconds and most dogs tolerate it with minimal discomfort.

What should I watch for after my dog has a Librela injection?

Watch your dog closely in the first week after each injection — this is when most reported adverse events occur. Contact your vet promptly if you notice: changes in how your dog walks — stumbling, unsteadiness, or weakness; seizure activity; sudden increase in thirst or urination; urinary incontinence; significant local swelling, pain, or redness at the injection site; lethargy disproportionate to their usual level; or any other change that concerns you. Most dogs have no significant reaction, but knowing what to watch for means you can act quickly if your dog is one of the minority who does.

Ask Dr. Waleed

Have a question about Librela or arthritis pain management for your senior dog? Send Dr. Waleed a message — I read every question and answer as many as I can.

Related Posts

• Signs of Arthritis in Senior Dogs: What Most Owners Miss

• Best Supplements for Senior Dog Joint Health: What Works and What Doesn't